The Nigeria Centre for Disease Control reported at least 221 deaths from Lassa fever during the first six months of this year [1].

The rising death toll underscores a critical public health challenge in Nigeria, where the disease continues to cause significant mortality during the first half of the year. The current fatality rate indicates a worsening trend compared to previous cycles, necessitating urgent intervention to prevent further loss of life.

Reports from the NCDC show a discrepancy in the total death toll for the period ending at epidemiological week 26. One report cited 221 deaths [1], while another report from the same agency listed the figure at 210 [2]. This range reflects the ongoing challenges of tracking outbreaks in real time across various regions.

In addition to the fatalities, the NCDC confirmed 842 cases of the viral hemorrhagic fever [2]. The case fatality rate has reached 24.9% [2], a figure that highlights the lethal nature of the virus when medical intervention is delayed or unavailable.

Health authorities said that stronger surveillance and early detection are necessary to curb the spread of the disease. The NCDC is urging the public to increase awareness of how the virus transmits and to seek medical help immediately upon the onset of symptoms.

Lassa fever is typically transmitted to humans through contact with food or household items contaminated with urine or feces from infected mastomys rats. Because the symptoms often mimic other common illnesses, early diagnosis remains a primary hurdle for healthcare providers in the affected areas.

“The Nigeria Centre for Disease Control reported at least 221 deaths from Lassa fever during the first six months of this year.”

The discrepancy in death tolls and the high case fatality rate suggest that Nigeria's healthcare infrastructure is struggling to keep pace with the Lassa fever outbreak. A fatality rate near 25% indicates that one in four confirmed patients is dying, pointing to gaps in early detection and the availability of effective antiviral treatments in rural areas.